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Abstract
Importance—Hypertension is prevalent among patients with psoriasis. The effect of psoriasis 
and its severity on hypertension control is unknown.
Objective—To determine the association between uncontrolled blood pressure and psoriasis, 
both overall and according to objectively measured psoriasis severity, among patients with 
diagnosed hypertension.
Design, Setting, and Participants—Population-based cross-sectional study nested in a 
prospective cohort drawn from The Health Improvement Network (THIN), an electronic medical 
records database broadly representative of the general population in the United Kingdom. The 
study population included a random sample of patients with psoriasis (n = 1322) between the ages 
of 25 and 64 years in THIN who were included in the Incident Health Outcomes and Psoriasis 
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Events prospective cohort and their age- and practice-matched controls without psoriasis (n = 11 
977). All included patients had a diagnosis of hypertension; their psoriasis diagnosis was 
confirmed and disease severity was classified by their general practitioners.
Main outcomes and measures—Uncontrolled hypertension was defined as a systolic blood 
pressure of 140 mm Hg or higher or a diastolic blood pressure of 90 mm Hg or higher based on 
the blood pressure recorded closest in time to the assessment of psoriasis severity.
Results—There was a significant positive dose-response relationship between uncontrolled 
hypertension and psoriasis severity as objectively determined by the affected body surface area in 
both unadjusted and adjusted analyses that controlled for age, sex, body mass index, smoking and 
alcohol use status, presence of comorbid conditions, and current use of antihypertensive 
medications and nonsteroidal anti-inflammatory drugs (adjusted odds ratio [aOR], 0.97; 95% CI, 
0.82-1.14 for mild psoriasis; aOR, 1.20; 95% CI, 0.99-1.45 for moderate psoriasis; and aOR, 1.48; 
95% CI, 1.08-2.04 for severe psoriasis; P = .01 for trend). The likelihood of uncontrolled 
hypertension among psoriasis overall was also increased, although not statistically significantly so 
(aOR, 1.10; 95% CI, 0.98-1.24).
Conclusions and Relevance—Among patients with hypertension, psoriasis was associated 
with a greater likelihood of uncontrolled hypertension in a dose-dependent manner, with the 
greatest likelihood observed among those with moderate to severe psoriasis defined by 3% or 
more of the body surface area affected. Our data suggest a need for more effective blood pressure 
management, particularly among patients with more severe psoriasis.
Psoriasis is a chronic inflammatory disease of the skin that affects 2% to 4% of the general 
population.1 Cardiovascular risk factors,2 such as metabolic syndrome3 and its individual 
components including hypertension,4 obesity,5 dyslipidemia,6 and diabetes mellitus,7 are 
more prevalent among patients with psoriasis compared with those without psoriasis, and the 
prevalence of each risk factor generally increases with greater psoriasis severity. An 
expanding body of epidemiologic data8-15 suggests that psoriasis, especially when more 
severe, is associated with an increased risk of major adverse cardiovascular events (ie, 
myocardial infarction, stroke, and cardiovascular mortality) independent of traditional 
cardiovascular risk factors. Hypertension is a major risk factor for the development of 
cardiovascular disease and, thus, an important modifiable cause of premature morbidity and 
mortality.16
Previous studies17-21 have indicated that the presence of comorbid disease, specifically 2 or 
more comorbidities, is associated with poorer treatment of each disease. Among patients 
with hypertension, there are scant and inconsistent data22,23 to suggest that a variety of 
comorbid diseases affect blood pressure control. To our knowledge, no prior study has 
specifically assessed the effect of psoriasis on blood pressure control among hypertensive 
patients. Therefore, the purpose of the present study was to investigate the effect of psoriasis 
and psoriasis severity (as defined objectively by affected body surface area [BSA]) on blood 
pressure control among patients with diagnosed hypertension in a broadly representative 
population-based cohort. We hypothesized that, among patients with hypertension, those 
with psoriasis would be more likely to have uncontrolled blood pressure than would patients 
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without psoriasis and that the relationship would be positively associated with greater 
psoriasis severity.
Methods
Study Design and Data Source
We conducted a population-based, cross-sectional study using The Health Improvement 
Network (THIN), a large (7.5 million patients from 415 practices) electronic medical 
records database maintained by general practitioners (GPs) and broadly representative of the 
United Kingdom. General practitioners, the gatekeepers of medicine in the United Kingdom, 
collect patients' demographic, diagnostic, treatment, and laboratory information using Vision 
software (In Practice Systems Ltd). THIN has been widely used and validated24 for the 
epidemiologic research of many diseases, including psoriasis. This study was conducted 
according to the STROBE (Strengthening the Reporting of Observational Studies in 
Epidemiology) statement and the Declaration of Helsinki and was granted exempt status by 
the University of Pennsylvania institutional review board. Study participants were registered 
in a practice with an Additional Information Services contract, which involves an agreement 
by the participants' GPs to complete questionnaires in exchange for financial compensation.
Study Population and Time of Observation
The Incident Health Outcomes and Psoriasis Events cohort was created by randomly 
sampling patients in THIN who were alive and aged 25 to 64 years at the time of sampling, 
had received at least 1 READ diagnostic code for psoriasis in the 2 years before sampling, 
and were registered in a practice with an Additional Information Services contract. Surveys 
with face and content validity designed by experts in epidemiology, dermatology, and 
primary care were sent to GPs of the sampled patients with psoriasis to verify the diagnosis 
and classify their disease extent via the National Psoriasis Foundation classification system 
as mild (limited disease with ≤2% BSA affected), moderate (scattered disease with 3%-10% 
BSA affected), or severe (extensive disease with >10% BSA affected), The exposed group 
consisted of patients with psoriasis READ diagnostic codes whose diagnosis and amount of 
skin involvement were verified by their GPs. The unexposed comparison group was 
constructed by randomly matching each psoriasis patient with up to 10 patients without 
psoriasis READ diagnostic codes who were from the same practice, in the same age 
category, and alive and actively registered with at least 1 GP visit within 2 years before 
sampling. To study the association between psoriasis severity and blood pressure control in 
patients with previously diagnosed hypertension, the study cohort was further restricted to 
patients with at least 1 READ diagnostic code for hypertension before or on the survey 
sampling date.
The start of the observation time was defined as the later of the acceptable mortality 
recording date and patient registration date in the practice. The end of the observation time 
was the date of GP survey sampling (November 2008 to September 2010). With the 
exception of blood pressure measurements, all covariates and laboratory values were 
assessed during the defined observation time window. Patients with any missing data or 
Takeshita et al. Page 3
JAMA Dermatol. Author manuscript; available in PMC 2016 January 27.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
those who died or transferred out of the GP's practice before the end of the observation time 
were excluded from the analyses.
Blood Pressure Outcome and Covariate Definitions
Blood pressure is well recorded in THIN, and GPs are incentivized to record blood pressure 
measurements for new patient screening and chronic disease monitoring.25 Systolic and 
diastolic blood pressure records closest to (before or after) the survey sampling date were 
used to determine blood pressure control in patients with and without psoriasis. Based on the 
UK National Institute of Health and Care Excellence26 clinical guidelines, uncontrolled 
hypertension was defined as systolic blood pressure of 140 mm Hg or higher or diastolic 
blood pressure of 90 mm Hg or higher. In addition to primarily determining the proportions 
of patients with uncontrolled hypertension, differences in the proportions of patients 
currently receiving any antihypertensive treatment among those with and without psoriasis 
were assessed secondarily.
To investigate the effect of psoriasis severity on blood pressure control independent of other 
risk factors, multiple potential confounders and effect modifiers, including age, sex, body 
mass index (BMI), smoking and alcohol use status, medical comorbidities (ie, diabetes 
mellitus, hyperlipidemia, chronic kidney disease, and cardiovascular disease), treatment 
patterns (history of cyclosporine or systemic corticosteroid use, and current antihypertensive 
therapy or nonsteroidal anti-inflammatory drug [NSAID] use), duration of observation time, 
frequency of blood pressure recordings, and time between the most recent blood pressure 
record and survey sampling date, were assessed in multivariable models. Age and BMI were 
treated as continuous variables. Comorbid medical conditions were assessed as prevalent 
cases (eg, a patient was identified as having diabetes if he or she received a diabetes READ 
diagnostic code on or before the survey sampling date), and cardiovascular disease was an 
aggregated covariate that included coronary artery disease, myocardial infarction, congestive 
heart failure, peripheral vascular disease, stroke, and transient ischemic attack. The effect of 
NSAID use on blood pressure control was investigated because NSAIDs may increase blood 
pressure among hypertensive patients27 and they are used to treat psoriatic arthritis, a 
condition that affects approximately 10% of patients with psoriasis.28,29 Current NSAID use 
was defined by the presence of a prescription for an NSAID within 30 days before the date 
of the blood pressure recording used to define the study outcome.30 Similarly, current 
antihypertensive use was defined by the presence of a prescription within 90 days before the 
date of the blood pressure recording used to define the study outcome; prior antihypertensive 
therapies were not considered. The 6 classes of antihypertensive treatments studied were 
angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, diuretics 
(including thiazide, loop, and potassium-sparing diuretics), β-blockers, calcium channel 
blockers, and centrally acting agents. In addition, hypertension severity was classified 
according to the Seventh Report of the Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure (JNC 7) criteria31 from least to most 
severe as follows: 0, controlled with lifestyle modifications; 1, monotherapy (excluding 
centrally acting agents); 2, dual therapy (excluding centrally acting agents); 3, triple therapy 
(excluding centrally acting agents); and 4, quadruple therapy and/or centrally acting agents. 
For time-varying variables, such as BMI and smoking and alcohol use status, the most 
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recent record before the survey sampling date was selected. The following potential 
confounders or effect modifiers were further explored in sensitivity analyses: duration of 
hypertension; frequency of blood pressure recordings; time between the most recent blood 
pressure record and the survey sampling date; hypertension severity; history of treatment 
with cyclosporine, of which hypertension is an adverse effect; history of systemic 
corticosteroid treatment, which may affect both psoriasis severity and blood pressure 
control; and comorbid joint disease.
Sample Size
The study was descriptive; thus, sample size was not determined a priori. All patients with 
psoriasis who met the inclusion criteria were included in the study, yielding 680, 469, and 
173 patients with mild, moderate, and severe psoriasis, respectively. All effect measures are 
reported with 95% CIs.
Statistical Analysis
Descriptive statistics were used to summarize patient demographics. Groups were compared 
using the Wilcoxon rank sum test for continuous variables and the χ2 test for categorical 
variables. Odds ratios (ORs) and 95% CIs for the association of blood pressure control with 
psoriasis overall and according to psoriasis severity were calculated using logistic 
regression. In multivariable analyses, a purposeful selection approach was used in which 
predetermined covariates (ie, age, sex, BMI, current antihypertensive use, and current 
NSAID use) were included in the model regardless of their P values, and additional 
covariates were included if their univariate associations with the exposure and outcome were 
significant (P < .10). To achieve the most parsimonious model, a backward selection 
approach was used to eliminate covariates in the full model with P > .05 for which removal 
did not change the point estimates of the exposure variables by greater than 10%. 
Interactions between age and psoriasis and between sex and psoriasis were explored in the 
primary model and between hypertension severity and psoriasis in sensitivity analyses and 
were included in the models if significant (P < .10). Multiple sensitivity analyses were 
performed to assess the robustness of our results. All analyses were performed using Stata, 
version 12 (StataCorp).
Results
Patient Characteristics
Of 10 474 eligible patients with psoriasis sampled, 10 026 had surveys returned by their GPs 
(95.7% response rate), of whom 9069 (90.5%) had their psoriasis diagnosis confirmed by 
their GP, and 8760 (96.6%) had their psoriasis extent determined (Figure). Of these patients, 
1322 (15.1%) had a diagnosis of hypertension, all of whom had at least 1 blood pressure 
record during the time of observation. Among the patients with diagnosed hypertension, 680 
(51.4%) had mild psoriasis (≤2% BSA), 469 (35.5%) had moderate psoriasis (3%-10% 
BSA), and 173 (13.1%) had severe psoriasis (BSA >10%). Psoriatic arthritis was diagnosed 
in 122 (9.2%) patients with hypertension, and 610 (46.1%) patients had a psoriasis diagnosis 
for at least 10 years. A similar selection algorithm for the comparison group consisting of 
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patients without psoriasis yielded 11 977 patients with diagnosed hypertension and at least 1 
blood pressure recorded.
Compared with patients without psoriasis, those with psoriasis had a higher median BMI (P 
< .001), more blood pressure records (P = .004), and a shorter time between the blood 
pressure record and survey sampling date (P = .01). In addition, patients with psoriasis were 
more likely to be former or active smokers (P < .001), have a history of cyclosporine (P < .
001) or systemic corticosteroid use (P = .002), be current users of NSAIDs (P < .001), and 
be receiving quadruple therapy and/or a centrally acting agent for hypertension (P = .01) 
(Table 1). Higher prevalences of diabetes (P < .001) and cardiovascular disease (P = .04) 
were observed in patients with psoriasis than in patients without psoriasis.
Blood Pressure Control in Psoriasis Patients With Hypertension
In unadjusted analyses, among psoriasis patients with diagnosed hypertension, there was a 
significant dose-response relationship between uncontrolled hypertension and objective 
measures of psoriasis severity as determined by the affected BSA: 344 (50.6%), 265 
(56.5%), and 103 (59.5%) patients with mild (BSA ≤2%), moderate (BSA 3%-10%), and 
severe (BSA >10%) psoriasis, respectively, had uncontrolled hypertension (P = .02 for 
trend).
After adjusting for age, sex, BMI, smoking and alcohol use status, the presence of comorbid 
conditions (diabetes mellitus, chronic kidney disease, hyperlipidemia, and cardiovascular 
disease), and current use of antihypertensive medications and NSAIDs, the dose-response 
relationship between uncontrolled hypertension and objectively measured psoriasis severity 
remained significant, with ORs of 0.97 (95% CI, 0.82-1.14), 1.20 (95% CI, 0.99-1.45), and 
1.48 (95% CI, 1.08-2.04) in patients with mild, moderate, and severe psoriasis, respectively 
(P = .01 for trend) (Table 2). The likelihood of having uncontrolled hypertension among all 
patients with psoriasis compared with those without psoriasis was similar in unadjusted and 
adjusted analyses and was found to be increased, although not statistically significantly so 
(adjusted OR, 1.10; 95% CI 0.98-1.24). The likelihood of uncontrolled hypertension was the 
greatest among patients with moderate and severe psoriasis. No significant interactions 
between age and psoriasis and between sex and psoriasis were identified in the adjusted 
model. Furthermore, in similarly adjusted analyses, patients with psoriasis were equally as 
likely to be currently receiving antihypertensive treatment as were patients without psoriasis 
(OR, 1.01; 95% CI, 0.86-1.18), and the likelihood of receiving antihypertensive therapy did 
not differ significantly by psoriasis severity (P = .38).
Sensitivity Analyses
We tested the robustness of our observations with multiple sensitivity analyses (Table 3). 
Our results were not altered by redefining the end of observation by the date of blood 
pressure records used in the primary analysis, which ensured that all covariates were present 
before the outcome assessment. To further minimize misclassification of psoriasis, we 
evaluated the main effects among patients whose psoriasis diagnoses were made by 
dermatologists and observed a strengthened overall association (OR, 1.26; 95% CI, 
1.06-1.50). Similarly, using a stricter definition of hypertension that required at least 2 
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hypertension READ diagnostic codes did not affect our findings, nor did adjusting for 
timing or frequency of blood pressure recordings. The results were also robust to exclusion 
of comorbid arthritic conditions (ie, psoriatic, rheumatoid, and osteoarthritis), indicating that 
the results were due to skin disease and not joint disease. Exclusion of patients with a history 
of cyclosporine treatment, of which hypertension is a potential adverse effect, did not 
attenuate our findings, nor did exclusion of patients with a history of systemic corticosteroid 
treatment, which may alter psoriasis severity and contribute to increased blood pressure. 
Alternative adjustment for antihypertensive therapy according to the JNC 7 criteria,31 which 
defines the severity of hypertension by number and classes of antihypertensive agents, also 
did not change the results. Finally, defining uncontrolled hypertension based on the mean of 
all blood pressure recordings within 12 months before the date of blood pressure 
measurement used in the primary analysis resulted in a stronger overall association (OR, 
1.15; 95% CI, 1.02-1.30), suggesting that use of a single blood pressure measurement is 
unlikely to result in overestimation of the association between psoriasis and uncontrolled 
hypertension.
Discussion
In our large population-based study of patients with psoriasis and diagnosed hypertension in 
the United Kingdom, we found a significant positive dose-response relationship between 
objective measures of psoriasis severity and uncontrolled hypertension as defined by a 
systolic blood pressure of 140 mm Hg or higher or a diastolic blood pressure of 90 mm Hg 
or higher measured in routine clinical practice, independent of potential risk factors for poor 
blood pressure control. The likelihood of uncontrolled hypertension in patients with vs 
without psoriasis was greatest among those with moderate and severe skin disease, 
representing nearly half of the psoriasis patients seen by GPs in the United Kingdom. Our 
results were robust to multiple sensitivity analyses performed to minimize misclassification 
of psoriasis and hypertension diagnoses, account for confounding owing to antihypertensive 
therapy, minimize detection bias by adjusting for the timing and number of blood pressure 
measurements, minimize any contribution from comorbid joint disease, and minimize any 
effect from cyclosporine or systemic corticosteroid treatment. Thus, collectively, our results 
suggest that, among patients with a diagnosis of hypertension, psoriasis (particularly 
moderate to severe disease), is independently associated with poorly controlled blood 
pressure.
Prior studies of hypertension in patients with psoriasis have primarily focused on 
measurements of the prevalence and incidence of hypertension. A meta-analysis4 of 
observational studies that assessed the association between psoriasis and hypertension 
confirmed an increased prevalence of hypertension among patients with psoriasis (OR, 1.58; 
95% CI, 1.42-1.76). In the same meta-analysis, the prevalence of hypertension was reported 
to increase with greater psoriasis severity (mild psoriasis: OR, 1.30; 95% CI, 1.15-1.47; 
severe psoriasis: OR, 1.49; 95% CI, 1.20-1.86). It is important to note that in these studies 
included in the meta-analysis, psoriasis severity was determined indirectly by psoriasis 
treatment patterns, and potential confounding variables were rarely adjusted for in 
multivariable analyses. Studies32,33 of incident hypertension have also suggested an 
increased risk of developing hypertension among patients with an established diagnosis of 
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psoriasis. A single study34 assessed the effect of psoriasis on hypertension severity (as 
defined by the JNC 7 criteria). In that clinic-based, case-control study, patients with 
psoriasis were more likely to require complex antihypertensive management than were those 
without psoriasis; the effect of psoriasis severity was not assessed. Our findings advance the 
current literature by showing a novel dose-dependent association between direct measures of 
psoriasis severity and uncontrolled hypertension as determined by routine clinic-based blood 
pressure measurements. Ours is also one of the few studies to examine the effect of a 
comorbid chronic inflammatory disease, such as psoriasis, on blood pressure control among 
patients with hypertension.
The pathophysiologic mechanisms of hypertension in patients with psoriasis remain 
unknown, although several biological pathways have been implicated, including 
overexpression of endothelin 1,35 a potent vasoconstrictor expressed in both vascular 
endothelium and keratinocytes; increased oxidative stress; and common inflammatory 
pathways, including key cytokines such as tumor necrosis factor and interleukin 17.36-39 
Upregulation of the renin-angiotensin signaling pathway may also promote the development 
of more difficult-to-control hypertension in patients with psoriasis. This hypothesis is 
supported by the observations of increased expression of the renin gene in lesional skin of 
patients with moderate to severe psoriasis compared with matched nonlesional skin40 and 
greater plasma renin activity and increased urinary aldosterone excretion in patients with 
psoriasis.41
The results of our study must be interpreted in light of its strengths and limitations. The 
strengths include the use of a large, population-based cohort broadly representative of the 
United Kingdom's general population and a high survey response rate for assessing 
psoriasis, which minimizes selection bias and enhances the external validity (ie, 
generalizability) of our findings. General practitioners were unaware of the hypotheses 
being tested, and ascertainment of blood pressure was nearly 100%, thus minimizing the 
potential for information bias. Misclassification of psoriasis severity was unlikely based on a 
previous finding42 that even untrained patients can reliably classify the severity of their 
psoriasis using methods similar to those used by the GPs in the present study. Limitations 
include the cross-sectional design, which prevents us from determining the directionality of 
the relationship between psoriasis severity and blood pressure control. Although we 
hypothesized that more severe psoriasis contributes to poorer blood pressure control, we 
cannot rule out the possibility that uncontrolled hypertension promotes more severe 
psoriasis. Misclassification of the outcome is another potential limitation because the 
determination of uncontrolled hypertension was based on a single blood pressure 
measurement recorded in the clinic rather than an aggregate of multiple blood pressure 
measurements and thus may overestimate poor blood pressure control. However, previous 
studies43,44 assessing the prevalence of uncontrolled hypertension found that using single vs 
multiple blood pressure readings to define uncontrolled hypertension resulted in similar 
prevalences, indicating that a single blood pressure measurement is representative of overall 
blood pressure control. Furthermore, any misclassification of uncontrolled hypertension 
would likely be nondifferential (ie, equally as likely in patients with and without psoriasis) 
and would have biased our results toward the null, resulting in conservative estimates of the 
true association. Indeed, our sensitivity analysis substituting the 12-month mean blood 
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pressure reading for the single reading used in the primary analysis supports this conjecture. 
Our findings may also be partially attributable to the choice of psoriasis therapy, most 
concerning of which would be cyclosporine, considering its association with hypertension. 
However, our results were robust to the exclusion of patients who had received 
cyclosporine, suggesting a minimal contribution of cyclosporine treatment to the observed 
association between psoriasis and uncontrolled hypertension. Based on prior data45,46 that 
suggest undertreatment of high blood pressure in psoriasis patients with diagnosed 
hypertension, our results may be interpreted to be attributable to differential management of 
hypertension in patients with and without psoriasis. However, in our adjusted multivariable 
analyses, we found patients with psoriasis to be equally as likely to receive antihypertensive 
treatment as those without psoriasis. Finally, although we controlled for several potential 
confounding factors, there may be additional unmeasured confounders, such as diet, 
physical activity, stress, and antihypertensive medication adherence, that were not included 
in our analyses and may have important effects on the association between psoriasis and 
uncontrolled hypertension.45
Conclusions
To our knowledge, this is the first study to investigate the effect of objectively measured 
psoriasis severity on blood pressure control and demonstrate a significant and increasing 
likelihood of uncontrolled hypertension among patients with more severe psoriasis, 
independent of other risk factors for poor blood pressure control. Adding to the currently 
limited understanding of the effects of comorbid disease on hypertension, our findings have 
important clinical implications, suggesting a need for more effective management of blood 
pressure in patients with psoriasis, especially those with more extensive skin involvement 
(ie, ≥3% BSA affected). Additional studies are needed to further characterize the effect of 
chronic inflammatory diseases, such as psoriasis, and its therapies on coexisting 
hypertension and its treatment in a longitudinal manner;to better understandthemechanisms 
underlying poor blood pressure control among patients with psoriasis; and to determine 
whether an improvement in hypertension management affects psoriasis severity.
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Figure. Study Population Selection
Flow diagram of exposed (psoriasis) and unexposed (no psoriasis) patients included in the 
study. BP indicates blood pressure; GP, general practitioner; and THIN, The Health 
Improvement Network.
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Table 1
Characteristics of the Study Population
Characteristic
No.(%)
P ValueaControl (n = 11 977) Psoriasis (n = 1322)
Age, median (IQR), y 57.0 (50.0-62.0) 57.0 (50.0-61.0)
.56b
Male sex 6109 (51.0) 711 (53.8) .06
Duration of observation, median (IQR), y 12.5 (8.9-18.2) 12.5 (9.2-18.2)
.71b
Time of BP recording from survey sampling date, median (IQR), d 52 (18-109) 46 (17-100)
.01b
Total No. of BP recordings, median (IQR) 26 (17-38) 27 (17-39)
.004b
BMI, median (IQR)c 28.6 (25.3-32.7) 29.8 (26.3-34.1) <.001b
Smoking statusc
 Never 5555 (46.4) 462 (34.9)
<.001 Former 4228 (35.3) 568 (43.0)
 Active 2176 (18.2) 291 (22.0)
Alcohol usec
 Never 1067 (8.9) 94 (7.1)
.08 Former 1094 (9.1) 127 (9.6)
 Active 9341 (78.0) 1054 (79.7)
Psoriasis severity
 Mild(BSA≤2%)
NA
680 (51.4)
NA Moderate (BSA 3%-10%) 469 (35.5)
 Severe (BSA >10%) 173 (13.1)
Psoriasis duration, yd
 <2-9
NA
704 (53.3)
NA 10-29 468 (35.4)
 ≥30 142 (10.7)
Psoriatic arthritis NA 122 (9.2) NA
History of cyclosporine use 26 (0.22) 27 (2.0) <.001
History of systemic corticosteroid use 2125 (17.7) 282 (21.3) .002
Current NSAID usee 1762 (14.7) 243 (18.4) <.001
Current antihypertensive usef,g 9426 (78.7) 1057 (79.9) .29
No. of antihypertensive therapies as a measure of hypertension severityh
 None 2551 (21.3) 265 (20.1)
.01
 Monotherapy 4108 (34.3) 459 (34.7)
 Dual therapy 3134 (26.2) 322 (24.4)
 Triple therapy 1171 (9.8) 127 (9.6)
 Quadruple therapy and/or centrally acting agent 1013 (8.5) 149 (11.3)
Hypertension duration, median (IQR), y 4.9 (2.3-8.1) 4.8 (2.0-8.3)
.69b
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Characteristic
No.(%)
P ValueaControl (n = 11 977) Psoriasis (n = 1322)
Comorbidities
 Diabetes mellitus 1943 (16.2) 265 (20.1) <.001
 Hyperlipidemia 3015 (25.2) 344 (26.0) .50
 Chronic kidney disease 1041 (8.7) 135 (10.2) .07
 Cardiovascular diseasei 1603 (13.4) 204 (15.4) .04
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); BP, blood pressure; BSA, body 
surface area; IQR, interquartile range; NA, not applicable; NSAID, nonsteroidal anti-inflammatory drug.
a
The χ2 test was used for analysis.
b
The Wilcoxon rank sum test was used for analysis.
c
Data for BMI, smoking, and alcohol use were available for 97.1%, 99.9%, and 96.1% of the patients, respectively, with no significant differences 
between patients with and without psoriasis.
d
Data for psoriasis duration were available for 99.4% of the patients.
e
Patients were considered to be currently receiving an NSAID if they had received a prescription within 30 days before the date of BP 
measurement.
f
Patients were considered to be currently receiving antihypertensive medication if they had received a prescription within 90 days before the date of 
BP measurement.
gClasses of antihypertensive medications included angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, β-blockers, calcium 
channel blockers, diuretics, and centrally acting agents.
hUsing the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 
criteria,31 hypertension severity was defined as follows from, least to most severe: 0, controlled with lifestyle modifications; 1, monotherapy 
(excluding centrally acting agents); 2, dual therapy (excluding centrally acting agents); 3, triple therapy (excluding centrally acting agents); and 4, 
quadruple therapy and/or centrally acting agent.
i
Included a history of coronary artery disease, myocardial infarction, congestive heart failure, peripheral vascular disease, stroke, or transient 
ischemic attack.
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